Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IDEAYA Biosciences, Inc. IDYA
$21.44
-$0 (-0.02%)
На 18:01, 12 мая 2023
+15.44%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1222827960.00000000
-
week52high
22.85
-
week52low
9.00
-
Revenue
50931000
-
P/E TTM
-16
-
Beta
0.83796100
-
EPS
-1.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:00
Описание компании
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 16 авг 2022 г. |
| Baird | Outperform | Outperform | 16 авг 2022 г. |
| Stifel | Hold | Buy | 15 авг 2022 г. |
| Stifel | Buy | Hold | 10 мар 2022 г. |
| Stifel | Hold | 23 сент 2021 г. | |
| Guggenheim | Buy | Buy | 13 сент 2022 г. |
| Citigroup | Buy | 27 окт 2022 г. | |
| Baird | Outperform | Outperform | 18 ноя 2022 г. |
| Capital One | Overweight | 28 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kelley Susan L. | A | 11000 | 11000 | 09 июн 2022 г. |
| YARNO WENDY L | A | 11000 | 11000 | 09 июн 2022 г. |
| SHANNON TIMOTHY M | A | 11000 | 11000 | 09 июн 2022 г. |
| ROSEN TERRY J | A | 11000 | 11000 | 09 июн 2022 г. |
| Morrison Scott W | A | 11000 | 11000 | 09 июн 2022 г. |
| Hampton Malcolm Garret | A | 11000 | 11000 | 09 июн 2022 г. |
| Stein Jeffrey | A | 11000 | 11000 | 09 июн 2022 г. |
| MACKEY CATHERINE J | A | 22000 | 22000 | 05 апр 2022 г. |
| Hata Yujiro S | A | 260000 | 260000 | 01 мар 2022 г. |
| WHITE MICHAEL ANTHONY | A | 92500 | 92500 | 01 мар 2022 г. |
Новостная лента
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 09:10
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.36 per share a year ago.
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
Zacks Investment Research
25 апр 2023 г. в 06:52
IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IDEAYA Biosciences shares jump on melanoma interim trial results
Proactive Investors
24 апр 2023 г. в 12:27
IDEAYA Biosciences shares jumped after the company posted additional positive interim results from its Phase 2 clinical trial evaluating its darovasertib and crizotinib combination in metastatic uveal melanoma (MUM) patients. As part of a clinical trial collaboration and drug supply agreement with Pfizer, IDEAYA is evaluating the combination of darovasertib, a potential first-in-class protein kinase C inhibitor, and crizotinib, a small molecule cMET inhibitor, in MUM.
Ideaya Biosciences Has A Strong Pipeline And Looks Investible
Seeking Alpha
24 мар 2023 г. в 16:24
IDEAYA Biosciences, Inc.'s platform is synthetic lethality targeting cancer. The company has produced solid proof of concept data from multiple programs.
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
07 мар 2023 г. в 08:16
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.28% and 48.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?